[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,099,158
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.79
  • Price/Sales 3.70
  • Price/Cash Flow 15.40
  • Price/Book 3.38

Options Overview Details

View History
  • Implied Volatility 38.70% (-0.16%)
  • Historical Volatility 24.99%
  • IV Percentile 63%
  • IV Rank 34.62%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 29) 8.25 (8.43%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 144
  • Volume Avg (30-Day) 557
  • Put/Call OI Ratio 1.21
  • Today's Open Interest 14,649
  • Open Int (30-Day) 15,166
  • Expected Range 89.59 to 106.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.60
  • Number of Estimates 7
  • High Estimate $1.73
  • Low Estimate $1.38
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +22.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.79 +4.93%
on 04/28/26
103.01 -5.48%
on 05/11/26
+0.44 (+0.45%)
since 04/20/26
3-Month
89.25 +9.09%
on 03/24/26
103.16 -5.62%
on 02/23/26
-3.96 (-3.91%)
since 02/20/26
52-Week
63.51 +53.30%
on 05/23/25
112.29 -13.30%
on 01/07/26
+32.06 (+49.10%)
since 05/20/25

Most Recent Stories

More News
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data ...

INCY : 96.75 (+1.20%)
Incyte Stock: Analyst Estimates & Ratings

As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

$SPX : 7,412.52 (+0.80%)
IBB : 167.03 (+1.73%)
INCY : 96.75 (+1.20%)
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. This press...

INCY : 96.75 (+1.20%)
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,...

INCY : 96.75 (+1.20%)
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious...

INCY : 96.75 (+1.20%)
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs)...

INCY : 96.75 (+1.20%)
2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore

2 Cash-Heavy Stocks with Solid Fundamentals and 1 We Ignore

INSP : 43.20 (+1.58%)
INCY : 96.75 (+1.20%)
RJF : 152.07 (+0.70%)
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Corporation (Nasdaq:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company’s new Executive Vice President and Chief Financial Officer, pursuant to...

INCY : 96.75 (+1.20%)
Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions

Incyte’s Q1 Earnings Call: Our Top 5 Analyst Questions

INCY : 96.75 (+1.20%)
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi ® (ruxolitinib) ...

INCY : 96.75 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 98.87
2nd Resistance Point 97.61
1st Resistance Point 96.61
Last Price 96.75
1st Support Level 94.35
2nd Support Level 93.09
3rd Support Level 92.09

See More

52-Week High 112.29
Last Price 96.75
Fibonacci 61.8% 93.66
Fibonacci 50% 87.90
Fibonacci 38.2% 82.14
52-Week Low 63.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.